Morgan Stanley’s $70 target on ELVN

ELVN Enliven Therapeutics Inc

$47 → $70 (+49%) by Oct 2027

Overweight · initiates · said Oct 2, 2026 · 12-month default horizon

Open: judged on the close on Oct 2, 2027

The article this target came from

Morgan Stanley initiates Enliven Therapeutics stock at overweight

Investing.com · Oct 2, 2026

price target of $70.00

Morgan Stanley’s track record → Enliven Therapeutics Inc →

A fact about what Morgan Stanley published, as reported by Investing.com, not a recommendation from Dalsna Finance; Morgan Stanley is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.